Note: This document contains side effect information about olutasidenib. Some dosage forms listed on this page may not apply to the brand name Rezlidhia.

Applies to olutasidenib: oral capsule.

Serious side effects of Rezlidhia

Along with its needed effects, olutasidenib (the active ingredient contained in Rezlidhia) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking olutasidenib:

More common

• Agitation
• bloody stools
• blue lips, fingernails, or skin
• blurred vision
• chest pain or tightness
• chills
• coma
• confusion
• cough
• decreased urine output
• depression
• dizziness
• eye pain
• fever
• general feeling of illness
• headache
• hostility
• irregular, fast or slow, or shallow breathing
• irritability
• lethargy
• muscle twitching
• nausea
• pounding in the ears
• rapid weight gain
• rectal bleeding
• seizures
• slow or fast heartbeat
• sore throat
• stomach pain or tenderness
• stupor
• swelling of the face, ankles, or hands
• trouble breathing
• unusual tiredness or weakness

Incidence not known

• Dark urine
• loss of appetite
• stomach pain, sever
• vomiting
• yellow eyes or skin

Other side effects of Rezlidhia

Some side effects of olutasidenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Bleeding gums
• body aches or pain
• bone pain
• constipation
• diarrhea
• difficulty in moving
• hoarseness
• irritation in the mouth
• joint pain
• mouth ulcers
• muscle pain or stiffness
• pain in the arms or legs
• redness and swelling of the gums
• stuffy or runny nose
• tender, swollen glands in the neck
• trouble in swallowing
• voice changes

For Healthcare Professionals

Applies to olutasidenib: oral capsule.

Cardiovascular

Frequency not reported: Electrocardiogram QT prolongation^[Ref]

Dermatologic

Very common (10% or more): Rash (24%)^[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (18%), constipation (26%), diarrhea (20%), mucositis (23%), nausea (38%), vomiting (17%)^[Ref]

General

-The most common (20% or greater frequency) adverse reactions, including laboratory abnormalities, were aspartate aminotransferase increased, alanine aminotransferase increased, potassium decreased, sodium decreased, alkaline phosphatase increased, nausea, creatinine increased, fatigue/malaise, arthralgia, constipation, lymphocytes increased, bilirubin increased, leukocytosis, uric acid increased, dyspnea, pyrexia, rash, lipase increased, mucositis, diarrhea and transaminitis.

-Serious adverse reactions were reported in 25% of patients which included differentiation syndrome (9%) and transaminitis (6%).

-Adverse reactions that led to permanent discontinuation of this drug were reported in 8% of patients which included transaminitis, differentiation syndrome, and gallbladder disorders.^[Ref]

Hematologic

Very common (10% or more): Differentiation syndrome (16%), hypertension (10%), leukocytosis (25%)^[Ref]

Hepatic

Very common (10% or more): Transaminitis (20%)

Frequency not reported: Biliary tract disorder, biliary colic, cholangitis, and cholestasis^[Ref]

Metabolic

Very common (10% or more): Decreased appetite (16%)^[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (28%)^[Ref]

Nervous system

Very common (10% or more): Headache (13%)^[Ref]

Other

Very common (10% or more): Edema (18%), fatigue/malaise (36%), pyrexia (24%)^[Ref]

Respiratory

Very common (10% or more): Cough (17%), dyspnea (24%)^[Ref]